Literature DB >> 31720407

Molecular genotyping to differentiate endogenous reactivation and exogenous reinfection of recurrent tuberculosis.

Shirly Suzana1, Sivakumar Shanmugam2, Swarna Latha P N2, Joy Sarojini Michael1.   

Abstract

Entities:  

Year:  2018        PMID: 31720407      PMCID: PMC6830134          DOI: 10.1016/j.jctube.2018.10.001

Source DB:  PubMed          Journal:  J Clin Tuberc Other Mycobact Dis        ISSN: 2405-5794


× No keyword cloud information.

Introduction

Tuberculosis (TB) is one of the leading causes of death worldwide. Currently one third of the world's population is infected by TB. Globally in 2016, 6.6 million people with TB were notified and reported to WHO. Of these, 6.3 million had new or relapse TB. India accounts for more than one quarter of the world's tuberculosis disease and deaths. In 2016, 2.8 million people were infected with TB in India (World Health Organization [1]. In a high burden country like India, there are many challenges faced by clinicians and public health programs in the control of TB even after improvements in TB diagnosis, treatment and prevention. One such problem is recurrent TB. After an effective standard short course of anti-tuberculosis treatment (ATT), some patients develop repeated tuberculosis disease with significant time interval between the first and the second episode of TB called as recurrent TB infection. The rate of recurrent TB varies from 0 to 14% in studies from around the world [2]. The recurrent TB may be due to endogenous reactivation or exogenous reinfection. When the first and the second episode of TB is caused by same strains of Mycobacterium tuberculosis it is called relapse or endogenous reactivation and when the first and the second episode of TB is caused by two different strains of Mycobacterium tuberculosis it is called exogenous reinfection. DNA finger printing techniques plays an important role to find out whether the recurrent TB infection is due to exogenous reinfection or endogenous reactivation. The genotyping tool uses different genetic markers and their positions in the genome to identify and differentiate the strains of Mycobacterium tuberculosis [3]. We have used Spoligotyping and 12 loci mycobacterial interspersed repetitive unit–variable number tandem repeats (MIRU–VNTR) techniques in this study to differentiate relapse and reinfection types of recurrent tuberculosis. Spoligotyping is a simple, rapid and highly reproducible genotyping tool and MIRU–VNTR is a reliable method which is considered as a gold standard genotyping technique [4]. Twelve loci MIRU–VNTR when used along with spoligotyping will increase the discrimination among the strains of Mycobacterium tuberculosis than using spoligotyping alone. The strains of Mycobacterium tuberculosis were isolated from patients during each episode of TB at the Department of Clinical Microbiology, Christian Medical College and Hospital, a tertiary care hospital receiving patients with tuberculosis from different parts of India. The first isolate was collected from newly diagnosed patients with tuberculosis and the second isolate was collected when they had any form of recurrent TB.

Materials and methods

Out of 500 bacteriologically confirmed patients with TB in this study, 22 patients had 2 episodes of tuberculosis over a period of 2 years from January 2014 and January 2016. The first isolate was collected from these 22 patients prior to TB treatment and the follow up cultures were collected anywhere between 7 to 16 months after the completion of 6 months of standard anti tuberculosis treatment(ATT) for their first episode of TB.

Culture

The samples were processed as per standard laboratory protocol [5] and were inoculated on Lowenstein–Jensen medium (L–J) and MGIT as per the standard laboratory protocol and manufacturers instruction respectively. Positive cultures were confirmed as M.tuberculosis by performing Ziehl–Neelsen (ZN) staining and M.tuberculosis complex by MPT64 detection using an immune chromatographic test by SD BIOLINE TB Ag MPT64 Rapid kit . Mycobacterium tuberculosis strains which grew in MGIT tubes were subcultured on to LJ slants and the isolates from LJ media were used for genotyping.

Drug susceptibility testing

Drug susceptibility test [6] of Mycobacterium tuberculosis isolates was done using 1% proportion method as per standard laboratory protocol (6). They were tested against first line drugs namely Streptomycin, Isoniazid, Rifampicin, Ethambutol. Doubling dilution of Mycobacterium tuberculosis isolates were inoculated on both drug containing and drug free LJ medium and incubated at 37 °C for 6 weeks. Growth of more than 1% on drug containing media as compared to drug free media were taken as drug resistant strains. Strains that were resistant to Isoniazid and Rifampicin were considered as multi drug resistant and they were subjected to second line DST.

Molecular typing

DNA extraction by CTAB NaCl method

About two loop full of bacteria were heat killed in 500 µl of TE buffer. After cooling, 80 µl of lysozyme (Sigma, USA) solution was added and incubated at 37 °C overnight. Following this 6 µl of proteinase K (Sigma, USA) and 80 µl of 10% sodium dodecyl sulphate (SDS) was added and incubated at 65 °C for 30 min.. After 30 min 100 µl of NaCl and 80 µl of Cetyl Trimethyl Ammonium BromideNaCl (CTABNaCl) was added and incubated at 65 °C for 30 min. Next 80 µl of chloroform isoamyl alcohol was added and centrifuged at 10,000 rpm for 20 min. The supernatant was transferred to fresh tubes with 500 µl of ice cold isopropanol and incubated at −20 °C overnight. The DNA was precipitated with ethanol and resuspended in 50 µl of 1× TE buffer.

Spoligotyping method

Spoligotyping was done at National Institute for Research In Tuberculosis (NIRT), Chennai by the method described by Kamerbeek et al. [7]. The direct repeat region in the genome of MTB complex was amplified using two primers DRa (5̍-CC AAG AGG GGA CGG AAA C-3̍) and DRb (5̍-GGT TTT GGG TCT GAC-3̍) .Chromosomal DNA of Mycobacterium tuberculosis strains H37Rv and M. bovis BCG P3 were used as positive controls and molecular grade (MQ) water was used as negative control. The amplified products were hybridized on Biodyne C membrane (Isogene Bioscience) which contained synthetic oligomeric spacer sequence derived from direct repeat region of M.tb and M.bovis BCG. The presence of spacers was visualized on X-ray films as black squares after incubation with streptavidin–peroxidase and the hybridization signals were detected using enhanced chemiluminescence (ECL) detection system.

MIRU–VNTR genotyping

Mycobacterial Interspersed Repetitive Unit–Variable–Number Tandem Repeats (MIRU–VNTR) typing has been widely used for genotyping of M. tuberculosis [8]. We have used MIRU–VNTR Genotyping Kit (GenoScreen, Lille, France) for the amplification of the 12 MIRU–VNTR loci and the 12 loci used were MIRU 2, 4, 10, 16, 20, 23, 24, 26, 27, 31, 39, 40. These 12 loci were considered as intergenic regions dispersed throughout the genome of M. tuberculosis. Chromosomal DNA of Mycobacterium tuberculosis strains H37Rv was used as a positive control and milli Q (MQ) molecular grade water was used as negative control.

Results

As shown in Fig. 1 we identified 22 patients with recurrent TB and all these patients had pulmonary TB. Out of 22 patients 19 were male and 3 were female. Their mean age was 35 years. Both the initial and the follow up isolates were collected from these 22 patients. Follow up cultures were collected from these patients anywhere between 7 to 16 months after the completion of 6 months of standard ATT treatment for their first episode of TB. In total we had 44 isolates from 22 patients from their 1st and 2nd episodes of their disease manifestation.
Fig. 1

Details of recurrence among patients with recurrent TB.

Details of recurrence among patients with recurrent TB. We have used two genotyping methods for better discrimination of M. tuberculosis isolates. Spoligotyping and 12 loci MIRU- VNTR was done for 44 isolates from these 22 patients. Patients whose 1st and 2nd isolates showed differences in genotype pattern were considered cases of exogenous reinfection, whereas patients those whose 1st and 2nd isolates had the same genotype pattern were considered as cases of endogenous reactivation. Table 1 shows the genotyping results using both Spoligotyping and MIRU–VNTR patterns of all patients. Out of the 22 patients, 13 had exogenous reinfection and 9 patients had endogenous reactivation. Out of 22 patients 14 (57%) had multi drug resistant TB (MDR–TB). Eight patients out of 14 patients with MDR–TB had exogenous reinfection.
Table 1

Genotyping results of paired isolates:.

S.NoAge/SexEpisodes/MonthsLineagesSpoligotype patternSIT No12 Loci MIRURecurrence
MIRU2MIRU4MIRU40MIRU10MIRU16MIRU20MIRU23MIRU24MIRU26MIRU27MIRU31MIRU39
15458080296016442059253126872996300731924348
122/F0EAI3_IND477,777,777,413,07111253432022364Endo
7EAI3_IND477,777,777,413,07111253432122364
238/M0Orphan770,377,740,000,140264224442461Exo
8Orphan400,377,740,000,771264524442464
337/M0EAI3_IND477,777,777,413,07111253430022364Exo
8EAI3_IND477,777,777,413,07111252432522364
418/M0EAI6_BGD777,777,757,413,371292242432522162Exo
11Orphan777,777,774,000,771222443201423
540/M0BEIJING000,000,000,003,7711225332515353Exo
9Orphan777,767,777,513,761252243451334
643/M0Orphan777,417,607,560,771255043536125Exo
8U777,777,777,700,771124223232516333
724/M0EAI5777,777,777,413,700138243432712341Endo
12EAI5777,777,777,413,700138243432712341
830/M0CAS1_DELHI703,777,740,003,77126222442513353Endo
9CAS1_DELHI703,777,740,003,77126522442513353
945/M0BEIJING000,000,000,003,7711225332515353Endo
13BEIJING000,000,000,003,7711223332515353
1021/M0BEIJING000,000,000,003,7711223322575353Exo
12Orphan777,777,777,703,771255043536025
1160/M0Orphan777,777,777,513,760255443536325Exo
14Orphan777,767,777,740,771255343526352
1240/M0EAI3_IND477,777,777,413,07111243432422343Endo
9EAI3_IND477,777,777,413,07111244432422343
1331/M0BEIJING000,000,000,003,371265225332515353Exo
15Orphan774,377,777,413,771255143536125
1424/M0T3777,723,777,760,7711655212512511322Exo
9H1777,777,774,020,77147223432515332
1530/M0BEIJING000,000,000,003,7711223232515354Exo
13LAM9777,777,607,760,77142125332514322
1653/M0EAI3_IND477,777,777,413,07111253432422343Endo
16EAI3_IND477,777,777,413,07111253432422343
1765/M0Orphan777,777,777,753,771233655442242Exo
10EAI1_SOM777,777,777,413,73148253432622352
1835/M0EAI5477,777,777,413,771126223432613341Endo
14EAI5477,777,777,413,771126223432612341
1948/M0BEIJING000,000,000,003,7711235332513353Endo
13BEIJING000,000,000,003,7711235332513353
2025/F0EAI3_IND477,777,777,413,07111252432622243Exo
14H1177,777,764,020,7711586222432215332
2120/F0EAI3_IND477,777,777,413,07111253432622365Exo
8CAS703,777,700,000,3711345223542617351
2228/M0BEIJING000,000,000,003,7711223332513354Endo
7BEIJING000,000,000,003,7711223332513354
Genotyping results of paired isolates:. Seven different strain lineages were found in this study. They were EAI, Beijing, U, CAS, T, H, and LAM. EAI and Beijing lineages were the predominant lineages in both exogenously and endogenously infected patients. As discussed in Table 1 there were four sub lineages of EAI. They were EAI3_IND -SIT 11(10), EAI5-SIT138(2) and SIT126(2), EAI1_SOM- SIT 48(1) and EAI6_BGD SIT 292(1).Beijing strains were under two SIT number -SIT 1(9) and SIT 255(1).CAS lineage was found in two sub lineages .Two isolates belonged to CAS1_DELHI sublineage with SIT 26 and CAS with SIT 1345 .There were two strains which belonged to H lineage (H1 SIT 47 and H4 SIT 778).The remaining three isolates were grouped under U, T and LAM lineages (U-SIT 1418, T3-SIT 1655) and LAM9-SIT 42 Out of 22 paired isolates, 21 pairs had correlation between spoligotyping and MIRU–VNTR results but only one pair which belonged to EAI3_IND(SIT 11) with similar spoligotype pattern had 3 loci difference among 12 loci in MIRU–VNTR analysis and hence considered as different strain of M. tuberculosis.

Discussion

Molecular epidemiological analysis has played a significant role to distinguish recent or reactivated infection where clinical or epidemiological data are absent. In this study, we have compared pretreatment isolates of M. tuberculosis with isolates at the time of recurrence with tuberculosis. In our study recurrent TB was more common among male when compared to female. Out of 22 patients, 19 patients were male and only 3 were female. A study by Corona et al from Mexico have reported the high prevalence of recurrent TB among males was due to poor adherence to anti tuberculosis treatment by men than women [9]. We found recurrent TB among patients with age group between 18 to 65 years and we could not find any significant correlation between recurrent TB and patients occupation. Similarly a study by Gadoev et al in 2017 from Uzbekistan have also reported that recurrent TB was not associated with any specific age group and occupation of patients in their study [10]. Among 22 patients with recurrent TB in this study, 59% had exogenous re infection and 41% had endogenous reactivation. These patients had exogenous reinfection within two years after completion of standard 6 months treatment with ATT. In contrast Vynnycky and Fine [11] from England reported that the exogenous reinfection is rare during the first 2 to 5 years after the first infection. These results suggested that in immunocompetent persons living in an area where tuberculosis is endemic, reinfection and progression to active disease might occur earlier than from patients in non-endemic countries. We have compared the rate of re infected and relapsed TB among HIV infected and HIV uninfected patients. Out of 22 patients with TB, 9 were HIV positive and the remaining 13 were HIV negative patients. As shown in Fig. 2, 8/9 (88%) HIV positive patients had recurrent TB due to exogenous reinfection. A study by Narayanan et al [12] from India in 2010 have also reported the high prevalence of exogenous re infection among HIV infected patients than HIV uninfected patients. The high rate of re infection among HIV infected patients may be due to the increased disease progression following exposure to TB in high endemic areas. Out of 13 HIV uninfected patients, 8(61%) had recurrent TB due to endogenous reactivation and 5(38%) had exogenous reinfection. Similarly [13] have reported the strong association of endogenous reactivation of TB in HIV uninfected patients.
Fig. 2

Recurrent TB among HIV infected and HIV Un infected patients.

Recurrent TB among HIV infected and HIV Un infected patients. Many previous studies have reported the contribution of MDR TB to TB recurrences [14].We also found that recurrence of TB was high among patients with MDR TB when compared to patients with drug susceptible TB. Out of 22 patients with recurrent TB, 14(63%) had multi drug resistant TB and 8(36%) patients had drug susceptible TB. Of which only 2 had recurrent TB caused by M. tuberculosis isolates which are multi drug resistant and both these patients had recurrence due to exogenous reinfection .The remaining 20 patients had recurrent TB due to drug susceptible M. tuberculosis isolates. Similarly a study by Small et al from California have reported exogenous reinfection with MDR strains in patients with recurrent TB and they have also stated that exogenous reinfection with multidrug-resistant M. tuberculosis can occur either during therapy for the original infection or after therapy has been completed [15]. In our study M. tuberculosis isolates causing exogenous reinfection were found in 7 different lineages. They are EAI, Beijing H, U, T, CAS and LAM .While isolates causing endogenous reactivation were found in only 3 lineage groups like EAI, CAS and Beijing. We found EAI lineage as the predominant lineage circulating among isolates causing exogenous reinfection as well as endogenous reactivation. Out of 23 isolates causing recurrent TB due to exogenous reinfection, 6 isolates belonged to EAI lineage and in 18 isolates which caused endogenous reactivation, 10 belonged to EAI lineage. Narayanan et al from Chennai in 2010 have reported previously a high prevalence of EAI lineage among isolates causing recurrent TB [16]. Beijing lineage accounted for 10 /44 (22%) of the total number of M. tuberculosis isolates and it was the second largest lineage in our study. Of the 10 Beijing lineage strains 6 were associated with endogenous reactivation. Similarly studies by Sun et al [17] and Lan et al [18] from Singapore and Vietnam respectively have reported the strong association of Beijing genotype with endogenous reactivation or relapse TB when compared to exogenous re infection. Laboratory studies have suggested that Beijing strains are better adapted for intracellular growth [19] and the greater flexibility to adverse conditions, such as by multidrug therapy might be the reasons for its association with relapse or reactivation form of recurrent TB [20].

Conclusion

We have found that molecular genotyping methods like Spoligotyping and MIRU–VNTR have been useful in differentiating Mycobacterium tuberculosis strains demonstrating whether a new episode of TB is caused by infection with the same strain as the previous episode or by a different strain. In this study recurrent TB was mainly due to exogenous reinfection than endogenous reactivation. Therefore patients who have been recently treated and cured of the disease should be counseled on possibilities of recurrence and advised on early detection and treatment. More efforts should also be made in educating the public in reducing the transmission of tuberculosis in the community.
  16 in total

1.  Association of Mycobacterium tuberculosis Beijing genotype with tuberculosis relapse in Singapore.

Authors:  Y-J Sun; A S G Lee; S-Y Wong; N I Paton
Journal:  Epidemiol Infect       Date:  2005-10-05       Impact factor: 2.451

2.  The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection.

Authors:  E Vynnycky; P E Fine
Journal:  Epidemiol Infect       Date:  1997-10       Impact factor: 2.451

3.  Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units.

Authors:  P Supply; S Lesjean; E Savine; K Kremer; D van Soolingen; C Locht
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology.

Authors:  J Kamerbeek; L Schouls; A Kolk; M van Agterveld; D van Soolingen; S Kuijper; A Bunschoten; H Molhuizen; R Shaw; M Goyal; J van Embden
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

5.  Impact of HIV infection on the recurrence of tuberculosis in South India.

Authors:  Sujatha Narayanan; Soumya Swaminathan; Philip Supply; Sivakumar Shanmugam; Gopalan Narendran; Lalitha Hari; Ranjani Ramachandran; Camille Locht; Mohideen Shaheed Jawahar; Paranji Raman Narayanan
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

6.  Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection.

Authors:  P M Small; R W Shafer; P C Hopewell; S P Singh; M J Murphy; E Desmond; M F Sierra; G K Schoolnik
Journal:  N Engl J Med       Date:  1993-04-22       Impact factor: 91.245

7.  DOTS for TB relapse in India: A systematic review.

Authors:  Gulrez Shah Azhar
Journal:  Lung India       Date:  2012-04

8.  Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance.

Authors:  Helen Cox; Yared Kebede; Sholpan Allamuratova; Gabit Ismailov; Zamira Davletmuratova; Graham Byrnes; Christine Stone; Stefan Niemann; Sabine Rüsch-Gerdes; Lucie Blok; Daribay Doshetov
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

9.  Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam.

Authors:  Nguyen Thi Ngoc Lan; Hoang Thi Kim Lien; Le B Tung; Martien W Borgdorff; Kristin Kremer; Dick van Soolingen
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

Review 10.  Current methods in the molecular typing of Mycobacterium tuberculosis and other mycobacteria.

Authors:  Tomasz Jagielski; Jakko van Ingen; Nalin Rastogi; Jarosław Dziadek; Paweł K Mazur; Jacek Bielecki
Journal:  Biomed Res Int       Date:  2014-01-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.